Holen Sie sich die Stockscreener-App
25.62
1.50%
-0.39
Schlusskurs vom Vortag:
$26.01
Offen:
$26.455
24-Stunden-Volumen:
583.36K
Relative Volume:
0.70
Marktkapitalisierung:
$1.65B
Einnahmen:
$32.08M
Nettoeinkommen (Verlust:
$-169.77M
KGV:
-9.0154
EPS:
-2.8418
Netto-Cashflow:
$-147.70M
1W Leistung:
+3.31%
1M Leistung:
-16.00%
6M Leistung:
-21.75%
1J Leistung:
+3.22%
1-Tages-Spanne:
$25.45
$26.45
1-Wochen-Bereich:
$24.20
$26.69
52-Wochen-Spanne:
$20.32
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
25.62 | 1.60B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics stock sits 35.28 percent below its high as Bo Cumbo joins board - AD HOC NEWS
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK) - Kalkine Media
A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account. - Stock Titan
Stoke Therapeutics stock reports USD 9.33 million Q2 revenue - AD HOC NEWS
Ruth Walker Appointed Vice President, People & Culture at Stoke Therapeutics - hrtoday.in
Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com India
[Form 3] Stoke Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share. - Stock Titan
Why Is Stoke Therapeutics, Inc. (STOK) Suddenly a Must-Watch Growth Stocks Name? - Kalkine Media
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Stoke Therapeutics, Inc. (STOK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, E - The National Law Review
Stoke Therapeutics appoints Bo Cumbo to board of directors By Investing.com - Investing.com Canada
STOK Looks 163.2% Overvalued on GF Value™ - GuruFocus
Stoke Therapeutics appoints Bo Cumbo to board of directors - Investing.com
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization - Business Wire
Stoke Therapeutics (NASDAQ:STOK) Shares Down 9%What's Next? - MarketBeat
Stoke Therapeutics Appoints Bo Cumbo to Its B - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
News - planetario.buenosaires.gob.ar
Stoke Therapeutics stock holds gains after recent data update - AD HOC NEWS
Stoke Therapeutics, Inc. (STOK) Investor Outlook: Exploring a 60.60% Potential Upside in Biotechnology - DirectorsTalk Interviews
ETFs Investing in Stoke Therapeutics, Inc. Stocks - TradingView
Stoke (STOK) Breaks Out with +4.23% Surge Past $30.54 2026-09-17Zero Lag EMA - siam.in
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)September 16, 2026 - BioSpace
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us
Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Stoke Therapeutics at Cantor conference: dravet data, cash runway - Investing.com
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - The Manila Times
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics grants inducement options to new CSO - scanx.trade
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock gains on Dravet data and Cantor conference plans - ad-hoc-news.de
BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com - Investing.com Nigeria
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Stoke Therapeutics Inc-Aktie (STOK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ticho Barry | CHIEF MEDICAL OFFICER |
Oct 01 '26 |
Sale |
26.16 |
1,051 |
27,494 |
19,059 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):